Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time

BJU International

Volumn 103, Issue 7, 2009, Pages 872-876

  Ng, Michael K ^a,b   Van As, Nicholas ^a   Thomas, Karen ^a   Woode Amissah, Ruth ^a   Horwich, Alan ^a   Huddart, Robert ^a   Khoo, Vincent ^b   Thompson, Alan ^b   Dearnaley, David ^a   Parker, Chris ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b Royal Marsden Hospital   (United Kingdom)

Author keywords

Active surveillance; Doubling time; Progression; PSA; Velocity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN FUNCTION; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RISK; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; VELOCITY;

AGED; AREA UNDER CURVE; BIOPSY; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; ROC CURVE;

EID: 62149112135     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08116.x     Document Type: Article

References (23)

1. Carter HB, Morrell CH, Pearson JD et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992 52 : 3323 8
2. D'Amico AV, Chen MH, Roehl KA et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004 351 : 125 35
3. D'Amico AV, Renshaw AA, Sussman B et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005 294 : 440 7
4. D'Amico AV, Cote K, Loffredo M et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002 20 : 4567 73
5. D'Amico AV, Moul JW, Carroll PR et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003 95 : 1376 83
6. Daskivich TJ, Regan MM, Oh WK. Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. J Urol 2006 176 : 1927 37
7. Scher HI, Eisenberger M, D'Amico AV et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004 22 : 537 56
8. Choo R, DeBoer G, Klotz L et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 2001 50 : 615 20
9. Stephenson AJ, Aprikian AG, Souhami L et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 2002 59 : 652 6
10. Fall K, Garmo H, Andren O et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007 99 : 526 32
11. Sengupta S, Myers RP, Slezak JM et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005 174 : 2191 6
12. van As NJ, Norman AR, Thomas K et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008 Epub ahead of print
13. Venkitaraman R, Norman A, Woode-Amissah R et al. Predictors of histological disease progression in untreated, localized prostate cancer. J Urol 2007 178 : 833 7
14. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983 148 : 839 43
15. Freedland SJ, Dorey F, Aronson WJ. Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy. Urology 2001 57 : 476 80
16. Loeb S, Kettermann A, Ferrucci L et al. PSA doubling time versus PSA velocity to predict high-risk prostate cancer. Data from the Baltimore Longitudinal Study of Aging. Eur Urol 2008 Epub ahead of print
17. King CR, Freedland SJ, Terris MK et al. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH. Urology 2007 69 : 732 7
18. Stamey TA, Caldwell M, McNeal JE et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004 172 : 1297 301
19. Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett 2007 249 : 30 9
20. Fan J, Upadhye S, Worster A. Understanding receiver operating characteristic (ROC) curves. CJEM 2006 8 : 19 20
21. Etzioni RD, Ankerst DP, Weiss NS et al. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst 2007 99 : 1510 5
22. Pinsky PF, Andriole G, Crawford ED et al. Prostate-specific antigen velocity and prostate cancer Gleason grade and stage. Cancer 2007 109 : 1689 95
23. Schroder FH, Roobol MJ, van der Kwast TH et al. Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol 2006 49 : 460 5